Clinical Trial Update: A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of DE-120 Injectable Solution for Age-related Macular Degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• DE-120 Injectable Solution (DE-120)

Snippet

Sponsor: Santen Inc. | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED